Sexual transmission of HIV and the law: an Australian medical consensus statement.
Criminal cases involving human immunodeficiency virus transmission or exposure require that courts correctly comprehend the rapidly evolving science of HIV transmission and the impact of an HIV diagnosis. This consensus statement, written by leading HIV clinicians and scientists, provides current scientific evidence to facilitate just outcomes in Australian criminal cases involving HIV.Main recommendations: Caution should be exercised when considering charges or prosecutions regarding HIV transmission or exposure because:Scientific evidence shows that the risk of HIV transmission during sex between partners of different HIV serostatus can be low, negligible or too low to quantify, even when the HIV-positive partner is not taking effective antiretroviral therapy, depending on the nature of the sexual act, the viral load of the partner with HIV, and whether a condom or pre-exposure prophylaxis is employed to reduce risk.The use of phylogenetic analysis in cases of suspected HIV transmission requires careful consideration of its limited probative value as evidence of causation of HIV infection, although such an approach may provide valuable information, particularly in relation to excluding HIV transmission between individuals.Most people recently infected with HIV are able to commence simple treatment providing them a normal and healthy life expectancy, largely comparable with their HIV-negative peers. Among people who have been diagnosed and are receiving treatment, HIV is rarely life threatening. People with HIV can conceive children with negligible risk to their partner and low risk to their child.Changes in management as result of the consensus statement: Given the limited risk of HIV transmission per sexual act and the limited long term harms experienced by most people recently diagnosed with HIV, appropriate care should be taken before HIV prosecutions are pursued. Careful attention should be paid to the best scientific evidence on HIV risk and harms, with consideration given to alternatives to prosecution, including public health management.
Lyell McEwin Hospital, University of Adelaide, Adelaide, SA Levinia.Crooks@ashm.org.au.
Mark
M
Boyd
Kirby Institute, University of New South Wales, Sydney, NSW.
David
D
Cooper
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW.
Elizabeth A
EA
Crock
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW.
Levinia
L
Crooks
Monash University, Melbourne, VIC.
Michelle L
ML
Giles
Kirby Institute, University of New South Wales, Sydney, NSW.
Andrew
A
Grulich
Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC.
Sharon R
SR
Lewin
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW.
David
D
Nolan
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, NSW.
Trent
T
Yarwood
D019380:Anti-HIV Agents / Q000627:therapeutic use; D001315:Australia; D032921:Consensus; D018562:Disease Transmission, Infectious / Q000331:legislation & jurisprudence* / Q000517:prevention & control*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans; D016365:Liability, Legal; D008297:Male; D011322:Primary Prevention / Q000331:legislation & jurisprudence*; D011634:Public Health / Q000331:legislation & jurisprudence; D012306:Risk; D012935:Social Justice
D019380:Anti-HIV Agents